Dexcom (DXCM) Current Deferred Revenue (2010 - 2025)

Dexcom (DXCM) has 16 years of Current Deferred Revenue data on file, last reported at $2.9 million in Q3 2025.

• On a quarterly basis, Current Deferred Revenue fell 79.14% year-over-year to $2.9 million in Q3 2025; TTM through Sep 2025 was $2.9 million, a 79.14% decrease from a year earlier, with the FY2024 full-year figure at $8.0 million, down 56.52% from the prior year.
• Current Deferred Revenue for Q3 2025 stood at $2.9 million, down from $6.1 million in the prior quarter.
• Over the last five years, Current Deferred Revenue for DXCM reached as high as $18.4 million in Q4 2023 and fell as low as $1.8 million in Q2 2021.
• Historically, Current Deferred Revenue has averaged $7.5 million across 5 years, with a median of $7.8 million in 2025.
• Across the five-year window, Current Deferred Revenue jumped 380.95% in 2022 and tumbled 79.14% in 2025, its largest moves.
• Year by year, Current Deferred Revenue stood at $2.1 million in 2021, then soared by 380.95% to $10.1 million in 2022, then soared by 82.18% to $18.4 million in 2023, then plunged by 56.52% to $8.0 million in 2024, then tumbled by 63.75% to $2.9 million in 2025.
• Per Business Quant data, the three most recent Current Deferred Revenue figures were $2.9 million in Q3 2025, $6.1 million in Q2 2025, and $7.8 million in Q1 2025.